Literature DB >> 21660151

Suppression of autophagy and activation of glycogen synthase kinase 3beta facilitate the aggregate formation of tau.

Song-In Kim1, Won-Ki Lee, Sang-Soo Kang, Sue-Young Lee, Myeong-Ja Jeong, Hee Jae Lee, Sung-Soo Kim, Gall V W Johnson, Wanjoo Chun.   

Abstract

Neurofibrillary tangle (NFT) is a characteristic hallmark of Alzheimer's disease. GSK3β has been reported to play a major role in the NFT formation of tau. Dysfunction of autophagy might facilitate the aggregate formation of tau. The present study examined the role of GSK3β-mediated phosphorylation of tau species on their autophagic degradation. We transfected wild type tau (T4), caspase-3-cleaved tau at Asp421 (T4C3), or pseudophosphorylated tau at Ser396/Ser404 (T4-2EC) in the presence of active or enzyme-inactive GSK3β. Trehalose and 3-methyladenine (3-MA) were used to enhance or inhibit autophagic activity, respectively. All tau species showed increased accumulation with 3-MA treatment whereas reduced with trehalose, indicating that tau undergoes autophagic degradation. However, T4C3 and T4-2EC showed abundant formation of oligomers than T4. Active GSK3β in the presence of 3-MA resulted in significantly increased formation of insoluble tau aggregates. These results indicate that GSK3β-mediated phosphorylation and compromised autophagic activity significantly contribute to tau aggregation.

Entities:  

Keywords:  Autopahgy; Glycogen synthase kinase 3β; Neurofibrillary tangles; Tau; Trehalose

Year:  2011        PMID: 21660151      PMCID: PMC3104199          DOI: 10.4196/kjpp.2011.15.2.107

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  30 in total

Review 1.  Pathways of tau fibrillization.

Authors:  Jeff Kuret; Carmen N Chirita; Erin E Congdon; Theresa Kannanayakal; Guibin Li; Mihaela Necula; Haishan Yin; Qi Zhong
Journal:  Biochim Biophys Acta       Date:  2005-01-03

2.  Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease.

Authors:  Y Nakamura; M Takeda; H Suzuki; H Hattori; K Tada; S Hariguchi; S Hashimoto; T Nishimura
Journal:  Neurosci Lett       Date:  1991-09-16       Impact factor: 3.046

3.  Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules.

Authors:  S Lovestone; C L Hartley; J Pearce; B H Anderton
Journal:  Neuroscience       Date:  1996-08       Impact factor: 3.590

4.  Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation.

Authors:  Huiping Ding; Tori A Matthews; Gail V W Johnson
Journal:  J Biol Chem       Date:  2006-05-10       Impact factor: 5.157

5.  Tau is not normally degraded by the proteasome.

Authors:  Sébastien Feuillette; Olivier Blard; Magalie Lecourtois; Thierry Frébourg; Dominique Campion; Cécile Dumanchin
Journal:  J Neurosci Res       Date:  2005-05-01       Impact factor: 4.164

Review 6.  Tau phosphorylation in Alzheimer's disease: pathogen or protector?

Authors:  Hyoung-Gon Lee; George Perry; Paula I Moreira; Matthew R Garrett; Quan Liu; Xiongwei Zhu; Atsushi Takeda; Akihiko Nunomura; Mark A Smith
Journal:  Trends Mol Med       Date:  2005-04       Impact factor: 11.951

7.  Involvement of ROS in Curcumin-induced Autophagic Cell Death.

Authors:  Youn Ju Lee; Nam-Yi Kim; Young-Ah Suh; Chuhee Lee
Journal:  Korean J Physiol Pharmacol       Date:  2011-02-28       Impact factor: 2.016

8.  Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ.

Authors:  Jae-Hyeon Cho; Gail V W Johnson
Journal:  J Biol Chem       Date:  2004-10-19       Impact factor: 5.157

Review 9.  The role of tau phosphorylation and cleavage in neuronal cell death.

Authors:  Wanjoo Chun; Gail V W Johnson
Journal:  Front Biosci       Date:  2007-01-01

10.  Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease.

Authors:  A M Cataldo; D J Hamilton; J L Barnett; P A Paskevich; R A Nixon
Journal:  J Neurosci       Date:  1996-01       Impact factor: 6.167

View more
  7 in total

Review 1.  The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.

Authors:  Zhenzhen Liu; Tao Li; Ping Li; Nannan Wei; Zhiquan Zhao; Huimin Liang; Xinying Ji; Wenwu Chen; Mengzhou Xue; Jianshe Wei
Journal:  Oxid Med Cell Longev       Date:  2015-06-15       Impact factor: 6.543

2.  The importance of implementing proper selection of excipients in lupus clinical trials.

Authors:  S Muller; D J Wallace
Journal:  Lupus       Date:  2014-02-25       Impact factor: 2.911

3.  Novel functional roles of caspase-related genes in the regulation of apoptosis and autophagy.

Authors:  Ju-Hyun Shin; Sang-Hyun Min
Journal:  Korean J Physiol Pharmacol       Date:  2016-10-28       Impact factor: 2.016

Review 4.  Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation.

Authors:  Carolina Alquezar; Shruti Arya; Aimee W Kao
Journal:  Front Neurol       Date:  2021-01-07       Impact factor: 4.003

5.  Tau phosphorylation affects its axonal transport and degradation.

Authors:  Teresa Rodríguez-Martín; Inmaculada Cuchillo-Ibáñez; Wendy Noble; Fanon Nyenya; Brian H Anderton; Diane P Hanger
Journal:  Neurobiol Aging       Date:  2013-04-17       Impact factor: 4.673

6.  Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors.

Authors:  Sunhyo Kim; Ki Ju Choi; Sun-Jung Cho; Sang-Moon Yun; Jae-Pil Jeon; Young Ho Koh; Jihyun Song; Gail V W Johnson; Chulman Jo
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

7.  Sequestration of sorcin by aberrant forms of tau results in the defective calcium homeostasis.

Authors:  Song-In Kim; Hee Jae Lee; Sung-Soo Kim; Yong-Soo Kwon; Wanjoo Chun
Journal:  Korean J Physiol Pharmacol       Date:  2016-06-23       Impact factor: 2.016

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.